• Ingredion posted Q&A ahead of its 2026 annual meeting, addressing earnings communications, GLP-1 exposure, geopolitical risk, tariffs, supply chain resiliency.
• Management said it issues a press release each quarter with earnings.
• GLP-1 drugs seen as minimal near-term direct impact, with long-term opportunity tied to health-focused demand.
• Protein-fortification portfolio cited at more than 50% growth; sugar-reduction portfolio cited at high single-digit growth.
• Geopolitical conflict monitored for energy-price effects; impacts incorporated into full-year guidance, with mitigation via price increases, tariff offsets, localized supply chain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingredion Incorporated published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.